• news.cision.com/
  • BICO Group/
  • CELLINK has been granted a patent for "Cellulose Nanofibrillar Bioink for 3D Bioprinting for Cell Culturing, Tissue Engineering and Regenerative Medicine Applications" from European Patent Office

CELLINK has been granted a patent for "Cellulose Nanofibrillar Bioink for 3D Bioprinting for Cell Culturing, Tissue Engineering and Regenerative Medicine Applications" from European Patent Office

Report this content

CELLINK has been granted a patent for its unique cellulose-based bioink technology enabling bioprinting of multiple cell types for tissue engineering and regenerative medicine applications. The patent protection applies to the European market, one of CELLINK’s most important markets.

The granted patent from the European Patent Office shows novelty, inventive step, and industrial applicability. This technology is used in CELLINK’s first universal bioink, CELLINK® Bioink, which has expanded into the CELLINK bioink Series (CELLINK® RGD, CELLINK® FIBRIN, CELLINK® SKIN, CELLINK® BONE and CELLINK® LAMININKs), designed to expand the possibilities of tissue-specific bioprinting.

In June 2020, the company received corresponding patent protection in the US market.

For research involving bioprinting cells such as fibroblasts, stem cells, retinal cells, chondrocytes, osteoblasts, lung cancer cells and liver cancer cells, the easy to use and biocompatible CELLINK Bioink offers reliable and precise control during the bioprinting process. This has been proven by numerous scientists working with bioprinted skin, multicellular, cartilage, bone and cancer tissue models for drug screening applications and regenerative medicine research.

We are very excited to expand the territories of granted patents for our CELLINK bioink Series to now include the European Union, an important market for us. Every day our passion for changing the future of medicine grows as we continue to see the direct results from our community of innovators using our CELLINK Bioink Series! Our collaborators are pushing the limits of science, enabling more predictive methods for drug development, disease modelling and advancing the field of tissue engineering. We now have customers in over 2,000 labs in 65+ countries and we are so proud of how far we have come together with our community. We are growing rapidly in multiple areas and, most importantly, moving closer to the patients. We know this patent will help us continue to achieve our goals.", says Dr. Héctor Martínez, CTO CELLINK.

The granted patent strengthens the company's protection for intellectual properties and complements a full portfolio of bioprinting solutions being developed at CELLINK. 

For further information, please contact:

Erik Gatenholm, CEO       
Phone (Sweden): +46 73 267 00 00
Phone (US): +1 (650) 515 5566
Email: eg@cellink.com   
Gusten Danielsson, CFO                            
Phone (Sweden): +46 70 991 86 04     
Phone (US): +1 (857) 332 2138

Email: gd@cellink.com

This is information that CELLINK AB (publ) submitted for publication, through the agency of the contact persons set out above, on June 29, 08:00 (CEST).

Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products, and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. CELLINK’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,700 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq the Stockholm under CLNK B. www.cellink.com/investors